Solventum Announces Secondary Offering Pricing

Solventum Corporation ( (SOLV) ) has provided an update.

On August 13, 2025, Solventum Corporation announced the pricing of a secondary offering of 8,800,000 shares of its common stock, which was sold by 3M Company, the selling shareholder. The offering, underwritten by Goldman Sachs & Co. LLC and BofA Securities, Inc., is expected to generate approximately $648 million in gross proceeds for 3M Company, with Solventum not receiving any proceeds from the sale. The transaction was registered under the Securities Act of 1933 and is expected to close on August 15, 2025, subject to customary conditions.

The most recent analyst rating on (SOLV) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Solventum Corporation stock, see the SOLV Stock Forecast page.

Spark’s Take on SOLV Stock

According to Spark, TipRanks’ AI Analyst, SOLV is a Neutral.

Solventum’s overall stock score reflects a mixed outlook. The most significant factor is the positive earnings call, which highlights increased guidance and strategic initiatives. However, financial performance is hindered by high leverage and declining profitability metrics. Technical analysis and valuation suggest caution, with the stock appearing overvalued and showing mixed technical signals.

To see Spark’s full report on SOLV stock, click here.

More about Solventum Corporation

Solventum Corporation operates in the healthcare industry, focusing on pioneering innovations at the intersection of health, material, and data science to improve patient outcomes and empower healthcare professionals.

Average Trading Volume: 941,286

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.69B

See more insights into SOLV stock on TipRanks’ Stock Analysis page.